Tempus

Tempus is an AI-powered precision medicine company that has built the world's largest library of clinical and molecular data, along with an operating system designed to make that data accessible and actionable — starting with cancer and expanding across multiple therapeutic areas. Founded in 2015 by Eric Lefkofsky following a personal experience with cancer in his family, Tempus has grown into a comprehensive platform serving healthcare providers, life sciences companies, and patients. The company's mission is to ensure patients receive the right drug at the right time, enabling longer and healthier lives through data-driven precision medicine.

Tempus serves a broad range of customers including physicians, health systems, academic medical centers, pharmaceutical companies, and biotech firms. Approximately 65% of all Academic Medical Centers in the United States are connected to the Tempus platform. The company's technology spans oncology, neurology and psychiatry, cardiology, radiology, and infectious disease, combining genomic testing, AI-enabled algorithms, real-world data, and clinical trial matching into a unified ecosystem.

Core Technology Platform

• Tempus ONE: An AI-enabled assistant designed for healthcare providers and researchers to support clinical decision-making and research workflows.
• Tempus NEXT: A solution focused on identifying and closing gaps in patient care.
• Tempus LENS: A tool enabling users to find, access, and analyze multimodal real-world data (RWD) for research and commercial purposes.
• Tempus ALGOS: Algorithmic models connected to Tempus assays that provide additional clinical insight beyond standard test results.

Oncology Solutions for Providers

• Genomic Profiling: Comprehensive molecular profiling of tumors to identify targeted therapy opportunities and inform treatment decisions.
• Algorithmic Tests: AI-driven tests that layer additional insights on top of genomic assay results.
• Tempus Hub: A centralized portal for providers to manage and access genomic and clinical data.
• Tempus+: An enhanced suite of oncology tools and services for providers.
• Clinical Trial Matching: Tools to identify potentially life-saving clinical trials for individual patients based on their molecular and clinical profiles.
• Digital Pathology: AI-assisted pathology solutions to support cancer diagnosis and characterization.
• Oncology Care Pathway Solutions: Structured guidance to support evidence-based oncology care delivery.
• EHR Integration: Seamless integration with electronic health record systems to embed Tempus insights into existing clinical workflows.
• Minimal Residual Disease (MRD) Testing: MRD testing now has new Medicare coverage for select indications when coverage criteria are met.

Neurology, Psychiatry, and Cardiology Solutions

• Tempus PRO™: A specialized solution for neurology and psychiatry providers to support diagnosis and treatment decisions.
• Notetaker: An AI-powered documentation tool designed to assist clinicians in neurology and psychiatry settings.
• ECG-AI: An AI-enabled electrocardiogram analysis tool to help identify underdiagnosed cardiac conditions.
• Tempus Pixel Cardio: An imaging AI solution for cardiology to support identification of underdiagnosed and undertreated patients.
• Cardiology Care Pathway Solutions: Tools to identify and address undertreated patients within cardiology care settings.

Radiology AI Solutions (Tempus Pixel)

• Tempus Pixel Therapy Response Evaluation: AI-assisted imaging analysis to evaluate patient response to therapy.
• Tempus Pixel Lung: Radiology AI focused on lung imaging analysis.
• Tempus Pixel Breast: AI-powered breast imaging solution for radiology workflows.
• Tempus Pixel Prostate: Imaging AI designed to support prostate cancer detection and evaluation.

Life Sciences Solutions

• Sequencing: Genomic and multi-omic sequencing services supporting pharmaceutical and biotech research.
• Real-World Data (RWD) and Tempus Lens: Access to multimodal real-world datasets for drug development, research, and commercialization.
• Biological Modeling: Computational modeling capabilities to support target discovery and drug development.
• Companion Diagnostics: Development and validation of companion diagnostic tests in partnership with life sciences companies.
• Omics Solutions: Comprehensive multi-omics services including genomics, transcriptomics, and related data types.
• CRO Services: Contract research organization services supporting clinical and translational research.
• Clinical Trials Execution and Enrollment: End-to-end support for designing, executing, and enrolling patients in clinical trials.
• Tempus Studies: Structured research study services leveraging the Tempus data platform.
• Care Gap Solutions: Tools to identify and address gaps in care relevant to life sciences commercialization strategies.
• AI-enabled Algorithms: Proprietary algorithmic models available to life sciences partners for drug development and patient stratification.

Scientific Research and Publications

• A Nature Biotechnology study demonstrated that the Tempus xT platform increases personalized therapeutic opportunities for cancer patients, with paired tumor/normal plus transcriptome sequencing outperforming tumor-only DNA panel testing.
• Tempus has developed a pan-cancer organoid platform for precision medicine, showcasing genomic and transcriptomic fidelity from over 1,000 patients and a neural-network-based approach for predicting patient-specific drug response heterogeneity across solid cancers.
• Research on liquid biopsy assays has validated that combining liquid biopsy with standard tissue genotyping captures actionable variants that would otherwise be missed by either approach alone.
• Tempus publishes research across oncology, neurology and psychiatry, cardiology, and infectious disease, contributing to the broader scientific community's understanding of precision medicine.

Through its integrated combination of AI technology, multimodal data, genomic testing, and clinical tools, Tempus is working to accelerate the discovery of novel therapeutic targets, predict treatment effectiveness, enable earlier disease diagnosis, and connect patients with life-saving clinical trials — representing a comprehensive vision for the future of data-driven precision medicine.